FDA
-
-
-
-
-
-
-
Wall Street Chases the Next Big Breakout
-
-
-
-
-
-
-
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
-
-
-
-
-
-
-
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
-
-
-
-
-
-
-
CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
-
-
-
-
-
-
-
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
-
-
-
-
-
-
-
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization
-
-
-
-
-
-
-
CervoMed (CRVO) Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
-
324,017 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

